Low-intensity focused ultrasound (LIFU)-activated nanodroplets as a theranostic agent for noninvasive cancer molecular imaging and drug delivery

2018 ◽  
Vol 6 (11) ◽  
pp. 2838-2849 ◽  
Author(s):  
Jianxin Liu ◽  
Fenfen Xu ◽  
Ju Huang ◽  
Jinshun Xu ◽  
Yang Liu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Molecular Imaging ◽  
Focused Ultrasound ◽  
Research Field ◽  
Low Intensity ◽  
Theranostic Agent ◽  
Therapeutic Drugs ◽  
Tumor Research

Theranostics is a new trend in the tumor research field, which involves the integration of diagnostic and therapeutic functions using imageable nanoparticles coupled with therapeutic drugs.

Low-intensity focused ultrasound mediated localized drug delivery for liver tumors in rabbits

Drug Delivery ◽  
2014 ◽  
Vol 23 (7) ◽  
pp. 2280-2289 ◽  
Author(s):  
Yuping Gong ◽  
Zhigang Wang ◽  
Guifang Dong ◽  
Yang Sun ◽  
Xi Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Focused Ultrasound ◽  
Liver Tumors ◽  
Low Intensity ◽  
Localized Drug Delivery

scholarly journals 19F MRI-guided Flexible Low-intensity Focused Ultrasound for Drug Delivery and Molecular Targeted Therapy

2021 ◽  
Author(s):  
Jie Yang ◽  
Yingbo Li ◽  
Jiemei Sun ◽  
Hongyan Zou ◽  
Qian Xie ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Targeted Therapy ◽  
Focused Ultrasound ◽  
Tumor Tissue ◽  
Local Drug Delivery ◽  
High Accumulation ◽  
Innovative Strategy ◽  
Low Intensity ◽  
On Demand ◽  
Mri Guided

Abstract Non-site-specific, time-release and inefficient tumor penetration remain the major obstacles to the clinical efficacy of anticancer drugs. Novel strategies are therefore urgently needed for developing stimuli-responsive, local drug delivery systems that can increase drug penetration and accumulation at tumor sites. Here, we firstly describe an on-demand drug delivery system, AZD9291-PFCE nanoparticles (NPs) with 19F magnetic resonance imaging (19F MRI)-guided flexible low-intensity focused ultrasound (LIFU). Optimized AZD9291-PFCE NPs (size 73.9 ± 1.9 nm) reach high accumulation in non–small cell lung cancer (NSCLC) tumor tissue. Further, LIFU triggered drug release from AZD9291-PFCE NPs and specifically increased tumor vascular and tumor tissue permeability. Quantitative 19F MRI was used to measure NPs accumulation in tumors in real-time after LIFU irradiation and to monitor therapeutic efficacy. Thus, we present an innovative strategy to achieve on-demand release of AZD9291 and improve NSCLC EGFR-targeted therapy efficacy by integrating theranostic NPs and 19F MRI-guided LIFU.

Low intensity focused ultrasound (LIFU) triggered drug release from cetuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma

2019 ◽  
Vol 7 (1) ◽  
pp. 196-210 ◽  
Author(s):  
Yang Wang ◽  
Guoqing Sui ◽  
Dengke Teng ◽  
Qimeihui Wang ◽  
Jia Qu ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Drug Release ◽  
Thyroid Carcinoma ◽  
Focused Ultrasound ◽  
Anaplastic Thyroid Carcinoma ◽  
Antitumor Therapy ◽  
Low Intensity ◽  
Targeted Ultrasound ◽  
Triggered Drug Release ◽  
Ultrasound Molecular Imaging

This study provides an efficient theranostic strategy for concurrent targeted ultrasound molecular imaging and effective synergistic antitumor therapy.

scholarly journals Focused ultrasound in neuro-oncology: the role of the Focused Ultrasound Foundation in driving adoption and innovation

2021 ◽  
Author(s):  
Emily C. Whipple ◽  
Camille A. Favero ◽  
Neal F. Kassell
Keyword(s):  
Drug Delivery ◽  
Brain Tumors ◽  
Focused Ultrasound ◽  
Clinical Evidence ◽  
Neurological Injury ◽  
High Concentration ◽  
Potential Applications ◽  
Tumor Agent

Abstract Introduction Intra-arterial (lA) delivery of therapeutic agents across the blood-brain barrier (BBB) is an evolving strategy which enables the distribution of high concentration therapeutics through a targeted vascular territory, while potentially limiting systemic toxicity. Studies have demonstrated lA methods to be safe and efficacious for a variety of therapeutics. However, further characterization of the clinical efficacy of lA therapy for the treatment of brain tumors and refinement of its potential applications are necessary. Methods We have reviewed the preclinical and clinical evidence supporting superselective intraarterial cerebral infusion (SSJACI) with BBB disruption for the treatment of brain tumors. In addition, we review ongoing clinical trials expanding the applicability and investigating the efficacy of lA therapy for the treatment of brain tumors. Results Trends in recent studies have embraced the use of SSIACI and less neurotoxic chemotherapies. The majority of trials continue to use mannitol as the preferred method of hyperosmolar BBB disruption. Recent preclinical and preliminary human investigations into the lA delivery of Bevacizumab have demonstrated its safety and efficacy as an anti-tumor agent both alone and in combination with chemotherapy. Conclusion lA drug delivery may significantly affect the way treatment are delivered to patients with brain tumors, and in particular GBM. With refinement and standardization of the techniques of lA drug delivery, improved drug selection and formulations, and the development of methods to minimize treatment-related neurological injury, lA therapy may offer significant benefits for the treatment of brain tumors.

Sign in / Sign up

Export Citation Format

Share Document